<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01218347</url>
  </required_header>
  <id_info>
    <org_study_id>SNUCPT10_Rosuvastatin_OATP1B1</org_study_id>
    <nct_id>NCT01218347</nct_id>
  </id_info>
  <brief_title>Influence of Organic Anion Transporting Polypeptide1B1(OATP1B1) Genotype on Rosuvastatin PK, PD and Lipid Profiles</brief_title>
  <acronym>OATP</acronym>
  <official_title>Influence of OATP1B1 Genotype on the Pharmacokinetics,Lipid Lowering Effect, and Lipid Profiles After Rosuvastatin Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aimed to explore the influence of organic anion transporting polypeptide1B1
      (OATP1B1) genotype on pharmacokinetics, lipid lowering effect and lipid profiles after
      rosuvastatin administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open, one arm, single sequence study for healthy volunteers are investigated. Thirty four
      subjects may be enrolled.

      Rosuvastatin are administered once a day for 21 days. Before and after rosuvastatin
      administration, PK, PD and lipid profiles are investigated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pharmacokinetic parameters(Tmax,Cmax,AUC) of rosuvastatin</measure>
    <time_frame>Day 21 0h, 1h, 2h, 3h, 4h, 5h, 8h, 12h, 24h</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>lipid panel(LDL,HDL,TG,Total cholesterol)</measure>
    <time_frame>Day 1 0h, Day 22 0h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lipid metabolites</measure>
    <time_frame>Day -1 0h, Day21 0h, 4h, 8h</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Organic Anion Transporting Polypeptide1B1 (OATP1B1)</condition>
  <condition>Rosuvastatin</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rosuvastatin treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>20 mg once daily for 21 days</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: Between 20 to 50 years of age, inclusive (age based on the date to give the
             informed consent)

          -  Weight: Over 55 kg, within Â±20% of ideal body weight

          -  Must be reliable and willing to make themselves available during the study period

          -  Must be willing to give blood sample for genotyping

        Exclusion Criteria:

          -  History of significant clinical illness needs medical caution, including
             cardiovascular, immunologic, hematologic, neuropsychiatric, respiratory,
             gastrointestinal, hepatic, or renal disease or other chronic disease

          -  History of a significant surgical resection of gastrointestinal tract except
             appendectomy

          -  History or evidence of drug abuse

          -  Use any medication during the last 14 days period before first dosing

          -  Hypersensitivity to HMG-CoA reductase inhibitor

          -  Judged to be inappropriate for the study by the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung-Sang Yu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University College of Medicine and Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Trials Center, Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2010</study_first_submitted>
  <study_first_submitted_qc>October 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2010</study_first_posted>
  <last_update_submitted>January 4, 2011</last_update_submitted>
  <last_update_submitted_qc>January 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2011</last_update_posted>
  <responsible_party>
    <name_title>Kyung-Sang Yu/Professor</name_title>
    <organization>Seoul National University Hospital</organization>
  </responsible_party>
  <keyword>OATP1B1</keyword>
  <keyword>rosuvastatin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

